^
    Contact us  to learn more about
    our Premium Content:  News alerts, weekly reports and conference planners
    DRUG:

    CBA-1535

    i
    Other names: CBA-1535, humanized anti 5T4/WAIF1 antibody, Tb535H
    Associations

    News

    Trials
    Company:
    Chiome Biosci
    Drug class:
    CD3 agonist, 5T4 inhibitor
    Related drugs:
    Associations

    News

    Trials
    over1year
    Preclinical characterization of CBA-1535, a novel bi-specific tribody, with two binding sites to 5T4 and one site to CD3ε (AACR 2023)
    These results provide the strong rationale for further clinical evaluation ofCBA-1535 in 5T4 positive tumors. CBA-1535 is now under the phase 1 trial in Japan (jRCT2031210708), with 2 parts, the monotherapy and the combination with Pembrolizumab.
    Preclinical • PD(L)-1 Biomarker • IO biomarker
    |
    IL6 (Interleukin 6) • TNFA (Tumor Necrosis Factor-Alpha) • IL2RA (Interleukin 2 receptor, alpha) • TPBG (Trophoblast Glycoprotein) • CD69 (CD69 Molecule) • IL2 (Interleukin 2) • AIF1 (Allograft Inflammatory Factor 1)
    |
    TPBG expression • TPBG positive
    |
    Keytruda (pembrolizumab) • CBA-1535